Pramipexole-5HT3 Antagonist Combination for Dose-Limiting GI Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression, including pramipexole, face challenges in achieving effective and safe dosages due to significant adverse effects, particularly at higher doses, limiting their therapeutic efficacy.
Innovation Solution
Combining pramipexole with a 5HT3-antagonist, such as ondansetron, reduces gastrointestinal side effects, allowing for higher and safer doses of pramipexole to be administered, thereby enhancing its antidepressant efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of pramipexole are used to treat depression, then antidepressant efficacy is improved, but gastrointestinal adverse effects worsen
Solution Approach 1:
A 5HT3-antagonist is introduced as an intermediary substance that blocks the harmful gastrointestinal effects of pramipexole without interfering with its antidepressant mechanism. The 5HT3-antagonist acts as a mediator that allows higher pramipexole doses to be tolerated by counteracting nausea and vomiting side effects through 5HT3 receptor blockade in the GI tract and chemoreceptor trigger zone.
2Reliability
If higher doses of pramipexole are used to achieve therapeutic effect, then treatment effectiveness is improved, but tolerability worsens
Solution Approach 1:
The invention converts the harmful gastrointestinal side effects of pramipexole into a beneficial situation by using the 5HT3-antagonist to block these effects. The same high dose of pramipexole that would normally cause intolerable nausea and vomiting is instead tolerated because the 5HT3-antagonist prevents these adverse effects, thereby converting a harmful scenario into a beneficial one where high efficacy is achieved without compromising tolerability.
3Object-generated harmful factors
If standard doses of pramipexole are used, then safety is improved, but antidepressant efficacy is limited
Solution Approach 1:
The invention changes the dosage parameter of pramipexole from standard Parkinson's disease doses to higher antidepressant doses by introducing the 5HT3-antagonist. This parameter change in pramipexole dosing is made possible because the 5HT3-antagonist counteracts the dose-limiting gastrointestinal side effects, thereby allowing the pramipexole dose to be increased beyond conventional limits while maintaining an acceptable safety profile.
Data Source
AI summary
The present invention describes the combination of a 5HT3-antagonist with pramipexole to reduce or eliminate the adverse effects associated with the use of pramipexole and to enable the use of high doses of pramipexole, useful for treating depressive disorders such as major depressive disorder.